Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.76 CHF | -1.02% | -0.77% | +56.77% |
Mar. 19 | Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 19 | Transcript : Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024 |
Sales 2024 * | 35.98M 38.8M 34.99M | Sales 2025 * | 25.95M 27.99M 25.24M | Capitalization | 149M 160M 145M |
---|---|---|---|---|---|
Net income 2024 * | 13M 14.02M 12.64M | Net income 2025 * | 4M 4.31M 3.89M | EV / Sales 2024 * | 4.94 x |
Net Debt 2024 * | 29.11M 31.4M 28.31M | Net Debt 2025 * | 2M 2.16M 1.95M | EV / Sales 2025 * | 5.8 x |
P/E ratio 2024 * |
10.2
x | P/E ratio 2025 * |
34.2
x | Employees | 22 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.09% |
Latest transcript on Newron Pharmaceuticals S.p.A.
1 day | -1.02% | ||
1 week | -0.77% | ||
Current month | -5.37% | ||
1 month | -6.51% | ||
3 months | +54.58% | ||
6 months | +43.70% | ||
Current year | +56.77% |
Managers | Title | Age | Since |
---|---|---|---|
Stefan Weber
CEO | Chief Executive Officer | 60 | 12-05-14 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Roberto Galli
DFI | Director of Finance/CFO | - | 01-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 07-12-31 | |
Joseph deBethizy
BRD | Director/Board Member | 74 | 13-12-31 |
Luca Benatti
FOU | Founder | 63 | 97-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 7.76 | -1.02% | 88,878 |
24-03-27 | 7.84 | +4.81% | 85,663 |
24-03-26 | 7.48 | -0.27% | 29,328 |
24-03-25 | 7.5 | +0.81% | 66,625 |
24-03-22 | 7.44 | -4.86% | 72,694 |
Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+56.77% | 161M | |
+0.44% | 90.27B | |
+9.61% | 44.05B | |
-16.67% | 31.45B | |
+44.99% | 23.35B | |
-9.42% | 16.72B | |
-25.92% | 15.09B | |
-9.27% | 12.82B | |
-7.57% | 11.95B | |
+0.07% | 8.71B |